227 related articles for article (PubMed ID: 18363956)
1. Cardiac manifestations of Anderson-Fabry disease in children and adolescents.
Kampmann C; Wiethoff CM; Whybra C; Baehner FA; Mengel E; Beck M
Acta Paediatr; 2008 Apr; 97(4):463-9. PubMed ID: 18363956
[TBL] [Abstract][Full Text] [Related]
2. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
3. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.
Takenaka T; Teraguchi H; Yoshida A; Taguchi S; Ninomiya K; Umekita Y; Yoshida H; Horinouchi M; Tabata K; Yonezawa S; Yoshimitsu M; Higuchi K; Nakao S; Anan R; Minagoe S; Tei C
J Cardiol; 2008 Feb; 51(1):50-9. PubMed ID: 18522775
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
5. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
6. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
7. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy.
Hoigné P; Attenhofer Jost CH; Duru F; Oechslin EN; Seifert B; Widmer U; Frischknecht B; Jenni R
Int J Cardiol; 2006 Aug; 111(3):413-22. PubMed ID: 16307805
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: cardiac manifestations and therapeutic options.
Pierre-Louis B; Kumar A; Frishman WH
Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
[TBL] [Abstract][Full Text] [Related]
9. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.
Shah JS; Hughes DA; Sachdev B; Tome M; Ward D; Lee P; Mehta AB; Elliott PM
Am J Cardiol; 2005 Sep; 96(6):842-6. PubMed ID: 16169374
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
[TBL] [Abstract][Full Text] [Related]
12. When should cardiologists suspect Anderson-Fabry disease?
Gambarin FI; Disabella E; Narula J; Diegoli M; Grasso M; Serio A; Favalli BM; Agozzino M; Tavazzi L; Fraser AG; Arbustini E
Am J Cardiol; 2010 Nov; 106(10):1492-9. PubMed ID: 21059442
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular manifestations in Fabry disease: a clinical and echocardiographic study.
Sadick N; Thomas L
Heart Lung Circ; 2007 Jun; 16(3):200-6. PubMed ID: 17452128
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
15. Altered myocardial motion pattern in Fabry patients assessed with CMR-tagging.
Rutz AK; Juli CF; Ryf S; Widmer U; Kozerke S; Eckhardt BP; Boesiger P
J Cardiovasc Magn Reson; 2007; 9(6):891-8. PubMed ID: 18066749
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.
Kampmann C; Wiethoff CM; Martin C; Wenzel A; Kampmann R; Whybra C; Miebach E; Beck M
Acta Paediatr Suppl; 2002; 91(439):21-7. PubMed ID: 12572838
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
[TBL] [Abstract][Full Text] [Related]
18. Cardiopulmonary exercise testing in Fabry disease.
Bierer G; Kamangar N; Balfe D; Wilcox WR; Mosenifar Z
Respiration; 2005; 72(5):504-11. PubMed ID: 16210890
[TBL] [Abstract][Full Text] [Related]
19. Clinical spectrum of Anderson Fabry disease in a Romanian family.
Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
